metavision biotech inc.

158-10 75th avenue
2f
fresh meadows, new york 11366

NYS Entity Status
ACTIVE

NYS Filing Date
APRIL 24, 2013

NYS DOS ID#
4393642

County
QUEENS

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2013 - METAVISION BIOTECH INC.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • Hamptons Property Asks $150 Million
    Thursday Jul 13, 2017

    The 14-acre beachfront spread on Meadow Lane in Southampton, N.Y., was assembled from four parcels of land and includes several homes.

    Source: The Wall Street Journal: Lifestyle
  • Atlas Venture Unveils New $350M Fund for Seed Biotech Investments
    By Frank Vinluan - Thursday Jun 29, 2017

    Life sciences venture capital firm Atlas Venture now has $350 million in fresh capital to invest in the early stage biotech companies in the U.S. and around the world. The new fund is Cambridge, MA-based Atlas’ eleventh. Atlas partner Bruce Booth says in a blog post that the firm began raising funds in April, bringing […]

    Source: Xconomy VC, Deals, & Startups Feed
  • Alexandria Debuts NY’s Latest Bio Incubator With 13 Startups in Tow
    By Ben Fidler - Tuesday Jun 13, 2017

    A new startup incubator has just opened in Manhattan this morning, adding to a growing list of facilities meant to help support seedling New York City biotechs. LaunchLabs, first announced by Alexandria Real Estate Equities a year ago, officially opened its doors and revealed the 13 startups that will grow there. LaunchLabs is a 15,000-square-foot […]

    Source: Xconomy New York
  • A Street Fight Among Grocers to Deliver Your Milk, Eggs, Bananas
    By RACHEL ABRAMS - Saturday Jun 24, 2017

    Bananas can’t get cold. Milk mustn’t tip. Online food delivery still trips up companies. A day on the truck shows why.

    Source: NYT > Home Page
  • Protagonist, Janssen Ink Development Deal for Crohn’s Disease Drug
    By Frank Vinluan - Tuesday May 30, 2017

    Protagonist Therapeutics’ work developing an inflammatory bowel disease drug that can be taken as a pill, rather than injected, now has fresh cash and the backing of a large pharmaceutical partner. Newark, CA-based Protagonist (NASDAQ: PTGX) has entered a partnership with Janssen Biotech to develop and commercialize its drug, PTG-200. Janssen is paying Protagonist $50 […]

    Source: Xconomy New York
metavision biotech inc fresh meadows ny